Vinge advises SEB Kort Bank AB in connection with its acquisition of Lufthansa AirPlus Servicekarten GmbH

June 21, 2023 M&A

SEB Kort Bank AB ("SEB Kort"), a wholly-owned subsidiary within the SEB Group, has entered into an agreement with Lufthansa Group to acquire all shares in Lufthansa AirPlus Servicekarten GmbH ("AirPlus").

Together, SEB Kort and AirPlus will become a leading European player in the corporate payments sector. For a cash consideration of EUR 450 million, the transaction will provide SEB Kort with additional scale, a strong position for further growth in Europe, and a modern IT platform. In addition, the transaction is expected to result in synergies and also complement SEB's broader ambitions in the corporate business in the DACH region (Germany, Austria, and Switzerland) and northern Europe.

In connection with the transaction, Vinge has acted as local counsel for SEB Kort and assisted with Swedish corporate and regulatory matters.

The transaction is, inter alia, subject to approvals from governmental authorities.

Vinge's team consisted of Daniel Rosvall and Viktor Lennartsson (M&A) as well as Caroline Krassén (Financial Services).


Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024